Tyrosine kinase inhibitors as cancer therapy

被引：6
|
作者：
Nichols, GL
机构：
[1] Columbia Univ Coll Phys & Surg, Dept Med, Div Hematol, New York, NY 10032 USA
[2] Columbia Univ Coll Phys & Surg, Dept Med, Div Oncol, New York, NY 10032 USA
来源：
CANCER INVESTIGATION | 2003年 / 21卷 / 05期
关键词：
tyrosine kinases; signal transduction; tyrosine kinase inhibitors; cancer therapy;
D O I：
10.1081/CNV-120023774
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：758 / 771
页数：14
相关论文
共 50 条
  • [41] Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management
    Sunder, Sunitha Shyam
    Sharma, Umesh C.
    Pokharel, Saraswati
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 8 (01)
  • [42] Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management
    Sunitha Shyam Sunder
    Umesh C. Sharma
    Saraswati Pokharel
    Signal Transduction and Targeted Therapy, 8
  • [43] Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
    Shuang Qin
    Anping Li
    Ming Yi
    Shengnan Yu
    Mingsheng Zhang
    Kongming Wu
    Journal of Hematology & Oncology, 12
  • [44] Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
    Qin, Shuang
    Li, Anping
    Yi, Ming
    Yu, Shengnan
    Zhang, Mingsheng
    Wu, Kongming
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (1)
  • [45] Systemic therapy of kidney cancer: tyrosine kinase inhibitors, antiangiogenesis or IL-2?
    Kirkali, Ziya
    Tuzel, Emre
    FUTURE ONCOLOGY, 2009, 5 (06) : 871 - 888
  • [46] Discovery and characterization of potent and selective AXL receptor tyrosine kinase inhibitors for cancer therapy
    Miles, D.
    Chen, Y.
    Paprcka, S. L.
    Foley, C. N.
    Grange, R.
    Leleti, M. R.
    Zhao, X.
    Jin, L.
    Young, S. W.
    Walters, M. J.
    Powers, J. P.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S38 - S39
  • [47] Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer
    Yang, Xue
    Wu, Dapeng
    Yuan, Shengli
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2020, 19
  • [48] Molecular targets of tyrosine kinase inhibitors in thyroid cancer
    Fallahi, Poupak
    Ferrari, Silvia Martina
    Galdiero, Maria Rosaria
    Varricchi, Gilda
    Elia, Giusy
    Ragusa, Francesca
    Paparo, Sabrina Rosaria
    Benvenga, Salvatore
    Antonelli, Alessandro
    SEMINARS IN CANCER BIOLOGY, 2022, 79 : 180 - 196
  • [49] Biomarkers for tyrosine kinase inhibitors in renal cell cancer
    Coupe, Nicholas
    Harrison, Michelle
    Chua, Wei
    de Souza, Paul
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2012, 1 (04) : 216 - 222
  • [50] Advances in MET tyrosine kinase inhibitors in gastric cancer
    Yifan Zhang
    Lin Shen
    Zhi Peng
    Cancer Biology & Medicine, 2024, 21 (06) : 484 - 498
12345